Monte Financial Statements From 2010 to 2026

Stocks . USA . 
Stock . Monte Rosa Therapeutics
GLUE Stock  USD 15.31  0.37  2.36%   
Monte Rosa's financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Monte Rosa's valuation are provided below:
Gross Profit
51 M
Profit Margin
0.1154
Market Capitalization
997 M
Enterprise Value Revenue
3.5577
Revenue
181.5 M
There are over one hundred nineteen available fundamental ratios for Monte Rosa, which can be analyzed over time and compared to other ratios. Investors should ensure to check all of Monte Rosa's last-minute performance against the performance from 2010 to 2026 to make sure the company is sustainable down the road. The current year's Market Cap is expected to grow to about 729.1 M. The current year's Enterprise Value is expected to grow to about 619.7 M

Monte Rosa Total Revenue

91.31 Million

Check Monte Rosa financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Monte Rosa's main balance sheet or income statement drivers, such as Net Interest Income of 12.8 M, Depreciation And Amortization of 9.8 M or Interest Expense of 4.5 M, as well as many indicators such as Price To Sales Ratio of 5.42, Dividend Yield of 0.0 or PTB Ratio of 2.17. Monte financial statements analysis is a perfect complement when working with Monte Rosa Valuation or Volatility modules.
  
Build AI portfolio with Monte Stock
Check out the analysis of Monte Rosa Correlation against competitors.

Monte Rosa Balance Sheet

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Total Assets277.1 M504.5 M140.8 M
Slightly volatile
Short and Long Term Debt Total44.9 M49.1 M20.7 M
Slightly volatile
Other Current Liabilities14.8 M21.6 M7.1 M
Slightly volatile
Total Current Liabilities189.5 M180.5 M40.5 M
Slightly volatile
Property Plant And Equipment Net36.5 M64.8 M18.4 M
Slightly volatile
Accounts Payable20.8 M19.8 M7.2 M
Slightly volatile
Cash146.9 M257.9 M74.1 M
Slightly volatile
Non Current Assets Total40.4 M70.5 M20.2 M
Slightly volatile
Cash And Short Term Investments231.2 M428 M116.1 M
Slightly volatile
Net Receivables189 K198.9 K998.1 K
Slightly volatile
Common Stock Total Equity4.3 K4.5 K31.2 K
Slightly volatile
Common Stock Shares Outstanding56.3 M85 M49.7 M
Slightly volatile
Liabilities And Stockholders Equity277.1 M504.5 M140.8 M
Slightly volatile
Non Current Liabilities Total49.9 M67.7 M33 M
Slightly volatile
Other Current Assets4 M5.9 M3.9 M
Slightly volatile
Other Stockholder Equity401.2 M764.6 M197.3 M
Slightly volatile
Total Liabilities260.6 M248.2 M74.7 M
Slightly volatile
Property Plant And Equipment Gross92.6 M88.2 M25.1 M
Slightly volatile
Short and Long Term Debt600 K675 K736.8 K
Slightly volatile
Total Current Assets236.8 M434.1 M120.6 M
Slightly volatile
Capital Stock9.6 K5.4 K31.6 K
Slightly volatile
Net Working Capital185.6 M253.6 M88.3 M
Slightly volatile
Short Term Debt3 M4.3 M1.8 M
Slightly volatile
Common Stock9.6 K5.4 K31.6 K
Slightly volatile
Property Plant Equipment32.7 M31.1 M10.3 M
Slightly volatile
Other Liabilities1.8 M1.8 M1.3 M
Slightly volatile
Non Currrent Assets Other4.6 M5.7 M2.5 M
Slightly volatile
Other Assets4.1 M5.3 M2.4 M
Slightly volatile
Capital Surpluse536.4 M579.3 M487.4 M
Slightly volatile
Non Current Liabilities Other26.2 M52.2 M14.2 M
Slightly volatile
Inventory768 K864 K943.1 K
Slightly volatile
Current Deferred Revenue74.2 M134.8 M33.7 M
Slightly volatile

Monte Rosa Income Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Depreciation And Amortization9.8 M9.3 M2.4 M
Slightly volatile
Interest Expense4.5 M4.3 M1.3 M
Slightly volatile
Selling General Administrative21.1 M40.4 M10.7 M
Slightly volatile
Other Operating Expenses95.6 M180.2 M51.1 M
Slightly volatile
Research Development73.3 M139.8 M39.9 M
Slightly volatile
Cost Of Revenue4.7 M9.3 M2.4 M
Slightly volatile
Total Operating Expenses92.8 M170.9 M49.5 M
Slightly volatile
Reconciled Depreciation9.8 M9.3 M2.3 M
Slightly volatile
Interest Income12.8 M12.2 M2.8 M
Slightly volatile
Selling And Marketing Expenses7.6 M8.5 M9.3 M
Slightly volatile

Monte Rosa Cash Flow Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Net Borrowings7.2 M8.1 M8.8 M
Slightly volatile
Begin Period Cash Flow109.7 M152.6 M51.6 M
Slightly volatile
Other Cashflows From Financing Activities62.5 M113.4 M38 M
Slightly volatile
Depreciation9.8 M9.3 M2.4 M
Slightly volatile
Capital Expenditures4.4 M4.6 M4.2 M
Slightly volatile
Total Cash From Financing Activities79.9 M89 M53.1 M
Slightly volatile
End Period Cash Flow151.1 M263.5 M77.8 M
Slightly volatile
Change To Liabilities245.4 K258.3 K20.8 M
Slightly volatile
Cash Flows Other Operating800 K571.5 K1.2 M
Slightly volatile

Financial Ratios

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio5.426.16.6625
Slightly volatile
Days Sales Outstanding0.670.750.8203
Slightly volatile
Stock Based Compensation To Revenue0.190.220.2356
Slightly volatile
Capex To Depreciation0.540.5612.4315
Slightly volatile
EV To Sales3.53.944.3044
Slightly volatile
Payables Turnover0.220.420.1816
Slightly volatile
Sales General And Administrative To Revenue0.380.420.4574
Slightly volatile
Research And Ddevelopement To Revenue1.291.451.5796
Slightly volatile
Capex To Revenue0.04220.04750.0518
Slightly volatile
Cash Per Share3.154.531.9146
Slightly volatile
Days Payables Outstanding84589010.1 K
Slightly volatile
Current Ratio2.062.163.9804
Pretty Stable
Receivables Turnover350393429
Slightly volatile
Capex Per Share0.04610.04860.082
Slightly volatile
Revenue Per Share0.820.921.0051
Slightly volatile
Interest Debt Per Share0.660.520.3832
Slightly volatile
Debt To Assets0.110.09740.1642
Pretty Stable
Operating Cycle0.670.750.8203
Slightly volatile
Days Of Payables Outstanding84589010.1 K
Slightly volatile
Ebt Per Ebit1.110.990.9912
Pretty Stable
Long Term Debt To Capitalization2.853.23.4969
Slightly volatile
Quick Ratio2.062.163.9804
Pretty Stable
Net Income Per E B T0.820.931.0091
Slightly volatile
Cash Ratio1.561.642.6893
Pretty Stable
Operating Cash Flow Sales Ratio0.450.50.5459
Slightly volatile
Days Of Sales Outstanding0.670.750.8203
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio1.291.041.1979
Pretty Stable
Fixed Asset Turnover1.071.211.319
Slightly volatile
Debt Ratio0.110.09740.1642
Pretty Stable
Price Sales Ratio5.426.16.6625
Slightly volatile
Asset Turnover0.140.160.1697
Slightly volatile
Gross Profit Margin0.710.80.8764
Slightly volatile

Monte Rosa Valuation Data

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Market Cap729.1 M589.9 M804.9 M
Slightly volatile
Enterprise Value619.7 M381.1 M748.3 M
Slightly volatile

Monte Fundamental Market Drivers

Forward Price Earnings10.02
Cash And Short Term Investments372.1 M

Monte Upcoming Events

21st of March 2024
Upcoming Quarterly Report
View
9th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
21st of March 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About Monte Rosa Financial Statements

Monte Rosa stakeholders use historical fundamental indicators, such as Monte Rosa's revenue or net income, to determine how well the company is positioned to perform in the future. Although Monte Rosa investors may analyze each financial statement separately, they are all interrelated. For example, changes in Monte Rosa's assets and liabilities are reflected in the revenues and expenses on Monte Rosa's income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Monte Rosa Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Current Deferred Revenue134.8 M74.2 M
Total Revenue87 M91.3 M
Cost Of Revenue9.3 M4.7 M
Stock Based Compensation To Revenue 0.22  0.19 
Sales General And Administrative To Revenue 0.42  0.38 
Research And Ddevelopement To Revenue 1.45  1.29 
Capex To Revenue 0.05  0.04 
Revenue Per Share 0.92  0.82 
Ebit Per Revenue(0.97)(1.01)

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
JBLJabil Circuit
MRKMerck Company
AMGNAmgen Inc
When determining whether Monte Rosa Therapeutics is a strong investment it is important to analyze Monte Rosa's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Monte Rosa's future performance. For an informed investment choice regarding Monte Stock, refer to the following important reports:
How To Invest In Monte
Details
Is Monte Stock a good investment?
Details
What is Monte Rosa's Net Worth?
Details
Largest Biotechnology Companies
View
Largest Pharmaceuticals, Biotechnology & Life Sciences Companies
View
Check out the analysis of Monte Rosa Correlation against competitors.
You can also try the My Watchlist Analysis module to analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Monte Rosa. If investors know Monte will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Monte Rosa listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
0.32
Revenue Per Share
2.208
Quarterly Revenue Growth
0.385
Return On Assets
0.0137
Return On Equity
0.0928
The market value of Monte Rosa Therapeutics is measured differently than its book value, which is the value of Monte that is recorded on the company's balance sheet. Investors also form their own opinion of Monte Rosa's value that differs from its market value or its book value, called intrinsic value, which is Monte Rosa's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Monte Rosa's market value can be influenced by many factors that don't directly affect Monte Rosa's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Altman
Z Score
Details
Piotroski
F Score
Details
Beneish
M Score
Details
Financial
Analysis
Details
Buy or Sell
Advice
Details
Earnings
Projections
Details
Please note, there is a significant difference between Monte Rosa's value and its price as these two are different measures arrived at by different means. Investors typically determine if Monte Rosa is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Monte Rosa's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2026 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY